4507:TYO
Shionogi & Co Ltd
2 762,50 ¥
arrow_downward
−0,02%(−0,50) 1 p
7. okt, 15:30:00 GMT +9 · JPY
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse 4507 põhistatistika genereerimine…
Ava
2 724 ¥
Kõrge
2 778 ¥
Madal
2 711 ¥
Turu kapit.
2,37Â trln
Keskm. maht
2,82Â mln
Maht
3,91Â mln
Dividend
2,57%
Kvartaalne dividend
18 ¥
Dividendikuupäev
29. sept 2026
Hinna ja tulu suhe
8,92
52 näd kõrgeim
3 758 ¥
52 näd madalaim
2 392 ¥
Aktsiatulu
310 ¥
Käibivad aktsiad
314,50Â mln
Töötajate arv
6Â tuh
Ava
2 724 ¥
Kõrge
2 778 ¥
Madal
2 711 ¥
Turu kapit.
2,37Â trln
Keskm. maht
2,82Â mln
Maht
3,91Â mln
Dividend
2,57%
Kvartaalne dividend
18 ¥
Dividendikuupäev
29. sept 2026
Hinna ja tulu suhe
8,92
52 näd kõrgeim
3 758 ¥
52 näd madalaim
2 392 ¥
Aktsiatulu
310 ¥
Käibivad aktsiad
314,50Â mln
Töötajate arv
6Â tuh
Uudised
Veebiallikatest ja uudistepartneritelt
Fierce Pharma
·
2 päeva eest
Shionogi strikes $2B deal for IntraBio hot off FDA label expansion
TipRanks
·
2 päeva eest
Shionogi to Buy IntraBio for $2 Billion, Bolstering Rare Disease Portfolio
Profiil
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
Teave üksuse Shionogi & Co Ltd kohta